What was REGENERON PHARMACEUTICALS, INC.'s revenue in fiscal 2025?

REGENERON PHARMACEUTICALS, INC. reported revenue of $14.34B for fiscal 2025, up 1.0% from fiscal 2024.

What is REGENERON PHARMACEUTICALS, INC.'s net margin?

Operating margin was 24.9% and net margin was 31.4%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

What is REGENERON PHARMACEUTICALS, INC.'s diluted EPS?

Diluted EPS was $41.48, up 8.2% from the prior year.

Are REGENERON PHARMACEUTICALS, INC. insiders buying or selling shares?

Over the past 12 months, insiders reported 78 open-market sales totalling $8.7M on Form 4.

Which institutions hold REGENERON PHARMACEUTICALS, INC. stock?

1,965 institutions reported holding REGENERON PHARMACEUTICALS, INC. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Vanguard Capital Management's.

Overview

REGENERON PHARMACEUTICALS, INC.

REGNNASDAQHealth CarePharmaceutical PreparationsCIK 0000872589Large-cap benchmark

Latest 10-K: FY2025, filed Feb 4, 2026 · Open the 10-K (Inline XBRL) ↗

Ask about REGN in Workspace

Revenue: $14.34B; 1.0%YoYup from FY2024; TotalRevenue
Gross profit: Not reported
Operating income: $3.58B; 10.3%YoYdown from FY2024; OperatingIncome
Net income: $4.50B; 2.1%YoYup from FY2024; NetIncome
Diluted EPS: $41.48; 8.2%YoYup from FY2024; EPSDiluted
Diluted shares: 108.6M; 5.6%YoYdown from FY2024; WeightedAvgSharesDiluted

At a glance

Growth

REGENERON PHARMACEUTICALS, INC. reported revenue of $14.34B for fiscal 2025, up 1.0% from fiscal 2024.
Revenue grew faster than the median S&P 500 member in 3 of the last 5 fiscal years.

Profitability

Operating margin was 24.9% and net margin was 31.4%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

Per share

Diluted EPS was $41.48, up 8.2% from the prior year.

Insiders & holders

Over the past 12 months, insiders reported 78 open-market sales totalling $8.7M on Form 4.
1,965 institutions reported holding REGENERON PHARMACEUTICALS, INC. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Vanguard Capital Management's.

Written from the filed figures on this page by fixed rules — no AI.

Data as of Oct 31, 2026 · Sources: SEC EDGAR 10-K, Form 4, 13F

Quick answers

What was REGENERON PHARMACEUTICALS, INC.'s revenue in fiscal 2025?: REGENERON PHARMACEUTICALS, INC. reported revenue of $14.34B for fiscal 2025, up 1.0% from fiscal 2024.
What is REGENERON PHARMACEUTICALS, INC.'s net margin?: Operating margin was 24.9% and net margin was 31.4%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.
What is REGENERON PHARMACEUTICALS, INC.'s diluted EPS?: Diluted EPS was $41.48, up 8.2% from the prior year.
Are REGENERON PHARMACEUTICALS, INC. insiders buying or selling shares?: Over the past 12 months, insiders reported 78 open-market sales totalling $8.7M on Form 4.
Which institutions hold REGENERON PHARMACEUTICALS, INC. stock?: 1,965 institutions reported holding REGENERON PHARMACEUTICALS, INC. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Vanguard Capital Management's.

Data as of Oct 31, 2026 · Sources: SEC EDGAR 10-K

Financial statements

Annual figures from the 10-K, most recent fiscal year first.

Income Statement

5 annual periods

Chip: YoY change.

Income Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Revenue	$14.34B1.0%up Benchmark median 6.4%	$14.20B8.3%up Benchmark median 4.5%	$13.12B7.8%up Benchmark median 4.8%	$12.17B24.3%down Benchmark median 10.3%	$16.07B89.1%up Benchmark median 13.8%	-2.8% Benchmark median 6.6%
Gross Profit Median of 315 / 498	—	—	—	—	—	— Benchmark median 6.2%
Operating Income Median of 373 / 498	$3.58B10.3%down Benchmark median 7.3%	$3.99B1.4%down Benchmark median 7.4%	$4.05B14.6%down Benchmark median 4.9%	$4.74B47.0%down Benchmark median 7.5%	$8.95B150.1%up Benchmark median 23.5%	-20.5% Benchmark median 7.2%
Net Income	$4.50B2.1%up Benchmark median 4.8%	$4.41B11.6%up Benchmark median 5.7%	$3.95B8.9%down Benchmark median 1.9%	$4.34B46.3%down Benchmark median 1.3%	$8.08B129.9%up Benchmark median 33.9%	-13.6% Benchmark median 4.1%
EPS (Diluted)	$41.488.2%up Benchmark median 6.2%	$38.3410.3%up Benchmark median 7.9%	$34.779.0%down Benchmark median 1.9%	$38.2246.9%down Benchmark median 1.5%	$71.97135.8%up Benchmark median 34.8%	-12.9% Benchmark median 5.6%

Balance Sheet

5 annual periods

Chip: YoY change.

Balance Sheet, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Total Assets	$40.56B7.4%up Benchmark median 5.6%	$37.76B14.1%up Benchmark median 3.4%	$33.08B13.2%up Benchmark median 4.1%	$29.21B14.9%up Benchmark median 2.2%	$25.43B48.2%up Benchmark median 6.7%	12.4% Benchmark median 4.7%
Total Liabilities Median of 357 / 498	$9.30B10.7%up Benchmark median 6.4%	$8.41B18.3%up Benchmark median 1.9%	$7.11B8.5%up Benchmark median 2.9%	$6.55B1.7%down Benchmark median 2.0%	$6.67B8.6%up Benchmark median 5.2%	8.7% Benchmark median 4.4%
Stockholders' Equity	$31.26B6.5%up Benchmark median 6.8%	$29.35B13.0%up Benchmark median 5.4%	$25.97B14.6%up Benchmark median 7.3%	$22.66B20.8%up Benchmark median 2.5%	$18.77B70.2%up Benchmark median 9.0%	13.6% Benchmark median 6.1%
Cash & Equivalents	$3.12B25.3%up Benchmark median 5.2%	$2.49B8.9%down Benchmark median 1.9%	$2.73B12.1%down Benchmark median 6.7%	$3.11B7.6%up Benchmark median -8.6%	$2.89B31.5%up Benchmark median -2.9%	2.0% Benchmark median 2.0%
Total Debt	$1.99B^†0.1%up Benchmark median 2.1%	$1.98B^†0.1%up Benchmark median 0.2%	$1.98B^†0.1%up Benchmark median 0.3%	$1.98B^†0.1%up Benchmark median 0.1%	$1.98B^†0.1%up Benchmark median -0.1%	0.1% Benchmark median 4.3%

† Sum of short-term and long-term debt; the company files no total-debt line.

Cash Flow Statement

5 annual periods

Chip: YoY change.

Cash Flow Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Operating Cash Flow	$4.98B12.6%up Benchmark median 6.3%	$4.42B3.8%down Benchmark median 4.8%	$4.59B8.4%down Benchmark median 9.9%	$5.01B29.2%down Benchmark median -0.7%	$7.08B170.5%up Benchmark median 10.7%	-8.4% Benchmark median 7.0%
Capital Expenditures	$898.40M18.9%up Benchmark median 5.4%	$755.90M5.2%up Benchmark median 2.8%	$718.60M21.8%up Benchmark median 11.3%	$590.10M6.9%up Benchmark median 14.0%	$551.90M10.2%down Benchmark median 8.1%	13.0% Benchmark median 9.0%
Free Cash Flow Median of 378 / 498	$4.08B11.3%up Benchmark median 7.3%	$3.66B5.4%down Benchmark median 6.1%	$3.88B12.4%down Benchmark median 8.8%	$4.42B32.2%down Benchmark median -11.3%	$6.53B225.9%up Benchmark median 10.2%	-11.1% Benchmark median 4.9%

n/m: not meaningful — the base (the prior year, or the first year for the CAGR) was zero or negative, or a per-share figure’s share basis changed (stock split). “—” means the figure is not available.

Benchmark median = median of the companies in the benchmark universe on Dec 31 of each fiscal year, from their own 10-K filings; a change counts only companies whose prior year was positive. Each median uses every member that reports the line item; where fewer than 80% do (banks and insurers file no gross profit), the row names how many. Published where at least 250 companies report it. Updated 2026-10-27. This compares reported figures, not share-price returns. Methodology

Ratios & valuation

FY2025

Every ratio read two ways: Wall Street’s popular formula and the value investor’s stricter one. Same question, same unit. Pick a ratio.

Valuation · Earnings yield

What a dollar of market value earned

5.4%

Wall Street

on net earnings

FY2024 5.4%

4.9%

Value investor

on free cash flow

FY2024 4.5%

Gap −0.5 pts: Value-investor figure 0.5 points lower

How it’s calculated

Wall Street · on net earnings

Diluted EPS ÷ fiscal-year-end share price (1 ÷ P/E)

pe_ratio (ratio table)

P/E 18.6×

Value investor · on free cash flow

(Operating cash flow − capital expenditures) ÷ market capitalisation (fiscal-year-end close × weighted-average diluted shares)

free cash flow ÷ market cap

Each ratio measures one thing two ways, in the same unit: the popular formula, then a stricter one, so a lower figure is the stricter reading. Gap = value-investor figure minus Wall Street figure, from the figures shown.

Price-based ratios use the fiscal-year-end closing price. Free cash flow = operating cash flow − capital expenditures (we compute it; filings rarely report it). n/m = not meaningful (denominator ≤ 0); “—” = not reported. Each ratio’s formulas are under “How it’s calculated”.

Cash & capital allocation

Where the cash went in FY2025, from the 10-K cash flow statement.

Operating cash flow: $4.98B
Capex: $898.40M
Free cash flow: $4.08B
R&D: $5.85B
Buybacks: $3.44B
Dividends: $370.30M
Debt repaid: —
Debt issued: —
Net debt change: —

Uses of operating cash flow, FY2025

Buybacks69.1%
Dividends7.4%
Capex18.0%

Each use is shown against operating cash flow on its own; the uses overlap.

Free cash flow by year

FY21$6.53B
FY22$4.42B
FY23$3.88B
FY24$3.66B
FY25$4.08B

Buybacks by year

FY21$1.65B
FY22$2.08B
FY23$2.23B
FY24$2.60B
FY25$3.44B

Smart money

Who is trading and holding REGENERON PHARMACEUTICALS, INC., from Form 4, 13F and 13D/13G filings.

Insiders

Insider activity · past 12 months

Open-market trades reported on Form 4 in the past 365 days.

Buys: 0; none reported
Sales: 78; 6 insiders
Value sold: $8.7M
Shares sold: 10,911
Net shares: -10,911; bought minus sold
Last trade: Sep 3, 2026

Purchases 0% of valueSales 100% of value

Latest open-market insider trades from Form 4
Insider	Type	Date	Shares	Price	Value	Filing
McCourt MarionEVP Commercial	Sell	Sep 3, 2026	1,131	$857.39	$969,708	View filing on SEC EDGAR
McCourt MarionEVP Commercial	Sell	Sep 2, 2026	1,215	$850.00	$1,032,750	View filing on SEC EDGAR
Guarini KathrynDirector	Sell	Sep 2, 2026	400	$850.00	$340,000	View filing on SEC EDGAR

See plans

Open-market purchases (code P) and sales (code S) only. Grants, option exercises and tax withholding are excluded. Sales may be made under pre-arranged Rule 10b5-1 plans.

Ownership

Largest institutional holders

13F

Quarter ended Jun 30, 2026; change versus Mar 31, 2026.

Institutions reporting: 1,965
Top 3 hold: 15.0%; of 108.60M diluted shares, FY2025 10-K

Top 3 holders, share of diluted sharesof 100%

Vanguard Capital Management6.1%
6,629,759 sh · $4.1BTrimmed 0.4%13F-HR · Jun 30, 2026 on SEC EDGAR
Dodge & Cox4.5%
4,871,137 sh · $3.0BAdded 9.3%13F-HR · Jun 30, 2026 on SEC EDGAR
STATE STREET CORP4.5%
4,834,688 sh · $3.0BAdded 3.6%13F-HR · Jun 30, 2026 on SEC EDGAR

See plans

Some filers' amendments could not be read, so a few holders may be counted twice.

Bars: share of diluted shares on a shared scale; the tick marks 5%. 13F filings are due 45 days after quarter end, so this is the latest fully reported quarter. Amended filings are counted once.

Blockholders, 5% and over

13D/G

SC 13D / 13G, latest filing per filer.

Filers at 5%+: 3
Combined: 22.2%; sum of latest filings
Activist (13D): 0

5%+ filers, share of the class as filedof 100%

BlackRock, Inc.8.1%
Passive · 13GLast filed 2 yrs agoSC 13G/A · Jan 25, 2024 on SEC EDGAR
Vanguard Capital Management7.37%
Passive · 13GSC 13G · Apr 30, 2026 on SEC EDGAR
ENTITIES ONLY)6.7%
Passive · 13GLast filed 2 yrs agoSC 13G/A · Jan 25, 2024 on SEC EDGAR

No filer switched from a passive 13G to an activist 13D in the last 365 days.

Percent of the class as each filer last reported it; filings older than a year may no longer reflect the stake. Latest filing per filer within three years; a later filing reporting 0% removes the filer.

Full history, every insider and 13F filer, 13D/G activist stakes, and webhooks are on Institutional.

See Institutional

Smart money

Showing the most recent 5 annual periods. Get longer history on the Pro plan, or the full history (1993–present) plus the smart-money dataset and webhooks on Institutional.

Restatement Radar

6 numbers REGENERON PHARMACEUTICALS, INC. later changed — same XBRL tag, both filings linked.

numbers changed: 6
restating filings: 4
came with an amendment or a non-reliance notice: 0

May 5, 2016 · 10-Q
changed 1 number
No amendment filed
Open filing
- Operating cash flowQ1 2015-$87.5M restated to -$101.7M−16.3%
  As reported · May 7, 2015us-gaap:NetCashProvidedByUsedInOperatingActivities
May 4, 2017 · 10-Q
changed 1 number
No amendment filed
Open filing
- Operating cash flowQ1 2016$29.3M restated to $45M+53.3%
  As reported · May 5, 2016us-gaap:NetCashProvidedByUsedInOperatingActivitiesAny P/OCF built on the original was 34.8% too high.
Feb 8, 2021 · 10-K
changed 3 numbers
No amendment filed
Open filing
- Total revenueFY 2018$6.7B restated to $5.1B−23.3%
  As reported · Feb 7, 2019us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxAny P/S built on the original was 30.4% too low.
- Total revenueQ1 2019$1.7B restated to $1.4B−19.8%
  As reported · May 7, 2019us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxAny P/S built on the original was 24.7% too low.
- Total revenueQ2 2019$1.9B restated to $1.6B−18.4%
  As reported · Aug 6, 2019us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxAny P/S built on the original was 22.6% too low.
Feb 7, 2022 · 10-K
changed 1 number
No amendment filed
Open filing
- Total revenueFY 2019$7.9B restated to $6.6B−16.6%
  As reported · Feb 7, 2020us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxAny P/S built on the original was 19.9% too low.

REGN is not the only one.

See every restatement we've found across the market — or get an alert the next time REGN revises a number.

Restatement Radar Alert me

Restatements are detected by comparing every vintage of a fact across all of REGENERON PHARMACEUTICALS, INC.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows REGN's most significant revisions, and a figure absent from it has not been certified as unrevised.

Peers, filings & research

Sector Peers

UNITEDHEALTH GROUP INC

MRK· Health Care

Merck & Co., Inc.

TMO· Health Care

THERMO FISHER SCIENTIFIC INC.

ABT· Health Care

ABBOTT LABORATORIES

ISRG· Health Care

INTUITIVE SURGICAL INC

AMGN· Health Care

AMGEN INC

Recent SEC filings

The six newest, periodic reports and 8-Ks together. Dates are SEC filing dates.

All filings on EDGAR

Six most recent SEC filings, newest first
Form	Filing	Filed	Document
8-K	Current report (material events) · Event dated Oct 30, 2026 0000872589-26-000032 · accepted 10:50 UTC	Oct 30, 2026	Open	Filed Oct 30, 2026 · 0000872589-26-000032
10-Q	Quarterly report · Quarter ended Sep 30, 2026 0000872589-26-000034 · accepted 10:55 UTC	Oct 30, 2026	Open	Filed Oct 30, 2026 · 0000872589-26-000034
8-K	Current report (material events) · Event dated Oct 1, 2026 0001104659-26-113895 · accepted 11:51 UTC	Oct 6, 2026	Open	Filed Oct 6, 2026 · 0001104659-26-113895
8-K	Current report (material events) · Event dated Sep 24, 2026 0001104659-26-112340 · accepted 20:14 UTC	Sep 30, 2026	Open	Filed Sep 30, 2026 · 0001104659-26-112340
10-K	Annual report · Fiscal year ended Dec 31, 2025 0000872589-26-000008 · accepted 14:08 UTC	Feb 4, 2026	Open	Filed Feb 4, 2026 · 0000872589-26-000008
10-K/A	Annual report amendment · Fiscal year ended Dec 31, 2009 0001206774-10-001385 · accepted 20:00 UTC	Jun 2, 2010	Open	Filed Jun 2, 2010 · 0001206774-10-001385

“Open” goes to the Inline XBRL viewer when the filing has one, else the primary document. The accession opens the EDGAR index.

Research Reports

No published research on REGN yet.

Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on REGN and publish the result to your public profile.

Browse the research catalog Generate one with your agent

The data behind this page

27 tables, history 1993–present. Every figure above is a row you can query.

Fundamentals

Standardized financial facts, ratios and filings.

fact: 121.4Mrows
ratio: 15.8Mrows
filing: 3.71Mrows
entity: 33,316rows

350+ standard concepts.

Built from these SEC forms

10-K
10-K/A
10-K405
10-K405/A
10-KT
10-KT/A
10-Q
10-Q/A
10-QT
10-QT/A
20-F
20-F/A
40-F
40-F/A
8-K
8-K/A
6-K
6-K/A
S-1
S-1/A
S-3
S-3/A
S-4
S-4/A
S-11
S-11/A
F-1
F-1/A
F-3
F-3/A
F-4
F-4/A
POS AM
10-KSB
10-KSB/A
10-QSB
10-QSB/A
DEF 14Asoon
DEF 14Csoon
DEFA14Asoon
PRE 14Asoon
DEFM14Asoon
425soon
SC TO-Tsoon
SC TO-Isoon
SC 14D9soon
SC 13E3soon
CORRESPsoon
NT 10-Ksoon
NT 10-Qsoon
NT 20-Fsoon
N-PORT-Psoon

Smart money

Insider and institutional filings.

institutional_holding: 88.6Mrows
insider_transaction: 12.1Mrows
insider_filing: 5.55Mrows
insider_ownership: 1.98Mrows

109M+ smart-money rows in all.

Built from these SEC forms

Form 3
Form 3/A
Form 4
Form 4/A
Form 5
Form 5/A
13F-HR
13F-HR/A
13F-NT
13F-NT/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
Form 144
Form 144/A

One real fact row for REGENERON PHARMACEUTICALS, INC.

Fact receiptOperatingCashFlow

Operating cash flow · FY2025

$4.98B

4,978,900,000 USD

REGENERON PHARMACEUTICALS, INC. reported Operating cash flow of $5.0B for fiscal year 2025 in its 10-K filed Feb 4, 2026.

Fiscal period: 2025 FY
Period end: 2025-12-31
Form: 10-K
Filed: Feb 4, 2026
Entity (CIK): 0000872589

Provenance trail

Filed with the SEC
Form 10-K, filed Feb 4, 2026.
Accession 0000872589-26-000008
Open in the Inline XBRL viewer for 0000872589-26-000008
Reported in the filing
Operating cash flow for fiscal year 2025, the period ended 2025-12-31, in USD. Valuein maps the filed line to the standard concept OperatingCashFlow.
Stored as one fact row
Every channel returns this row with the same id.
fact_id 5d66c99307751ac850fa1f9ad17bbe7141823ec74354f108f6b0439d36063cba
Shown on this page
The same $4.98B appears in the Cash Flow Statement and in Cash & capital allocation.

fact rowjson

{  "entity_id": "0000872589",  "standard_concept": "OperatingCashFlow",  "fiscal_year": 2025,  "fiscal_period": "FY",  "period_end": "2025-12-31",  "numeric_value": 4978900000,  "unit": "USD",  "accession": "0000872589-26-000008",  "fact_id": "5d66c99307751ac850fa1f9ad17bbe7141823ec74354f108f6b0439d36063cba"}

Get the same data

Get your free API key

bash

# Fact-level Parquet over HTTPS, every row traced to its filingcurl -H "Authorization: Bearer $VALUEIN_API_KEY" \  https://data.valuein.biz/v1/pro/fact/0000872589.parquet \  -o regn.parquet

Read the API docs

Terminalbash

# The same tables in your notebooks and backtests; the free sample needs no token$ pip install valuein-sdk

Python

from valuein_sdk import ValueinClient with ValueinClient() as client:    sql = """        SELECT fiscal_year, numeric_value FROM fact        WHERE entity_id = '0000872589'          AND standard_concept = 'TotalRevenue'          AND fiscal_period = 'FY'    """    print(client.run_query(sql))

Install the SDK

bash

# Connect Claude or ChatGPT to the same facts, each with a fact_idhttps://mcp.valuein.biz/mcp Ask your agent:get_company_fundamentals REGN   # CIK 0000872589

Connect the MCP server

bash

# Ask in plain English; every figure comes back cited to its filingTell me about REGN: a quick, cited overview I can dig into.

Open REGN in Workspace

One token unlocks every channel. SDK docs · MCP docs

Cite this page

Data as of Oct 31, 2026. Canonical address: https://valuein.biz/data/REGN

APA-style text

Valuein. (2026, October 31). REGENERON PHARMACEUTICALS, INC. (REGN) financial statements, earnings power and smart-money summary [Data set]. Source: SEC EDGAR filings. https://valuein.biz/data/REGN

BibTeX

@misc{valuein_regn_2026,
  author = {{Valuein}},
  title = {REGENERON PHARMACEUTICALS, INC. (REGN) financial statements, earnings power and smart-money summary},
  year = {2026},
  howpublished = {\url{https://valuein.biz/data/REGN}},
  note = {Data as of 2026-10-31; source: SEC EDGAR filings}
}

Open 10-K in SEC Inline XBRL viewer

10-K filed Feb 4, 2026 · accession 0000872589-26-000008

Agents: every figure Valuein's tools return carries a fact_id that traces to its SEC filing.

point-in-time · survivorship-free · every number traceable to its SEC filing

View REGN filings on SEC EDGAR

Index names are trademarks of their owners; Valuein is not affiliated with or endorsed by any index provider.

At a glance

Growth

Profitability

Per share

Insiders & holders

02Financial statements

Income Statement

Balance Sheet

Cash Flow Statement

Ratios & valuation

03Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

04Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders

Blockholders, 5% and over

Smart money

May 5, 2016 · 10-Q

May 4, 2017 · 10-Q

Feb 8, 2021 · 10-K

Feb 7, 2022 · 10-K

06Peers, filings & research

Sector Peers

Recent SEC filings

Research Reports

07The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

One real fact row for REGENERON PHARMACEUTICALS, INC.

Provenance trail

Get the same data

08Cite this page

Insiders & holders

03Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

04Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders

Blockholders, 5% and over

May 5, 2016 · 10-Q

May 4, 2017 · 10-Q

Feb 8, 2021 · 10-K

Feb 7, 2022 · 10-K

Sector Peers

Recent SEC filings

07The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

One real fact row for REGENERON PHARMACEUTICALS, INC.

Provenance trail

Get the same data

Financial statements

Cash & capital allocation

Smart money

Peers, filings & research

The data behind this page

Cite this page

Cash & capital allocation

Smart money

The data behind this page